Related Experiment Video
Updated: Jun 14, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.4K
Patients' experiences with GLP1-RAs - a systematic review
Christoffer Kraul Ibsen1, Marius Brostrøm Kousgaard1, Sofie Olsen1
1Center for General Practice, University of Copenhagen, Copenhagen, Denmark.
Scandinavian Journal of Primary Health Care
|March 12, 2025
Summary
Patients using glucagon-like peptide-1 receptor agonists (GLP1-RAs) for obesity accept side effects for weight loss and report improved well-being. Understanding patient experiences with these popular obesity medications is crucial.
Area of Science:
- Metabolic disorders
- Pharmacology
- Patient-reported outcomes
Background:
- Obesity is a significant public health issue with limited effective treatments.
- Glucagon-like peptide-1 receptor agonists (GLP1-RAs) show promise for significant weight loss.
- Patient experiences with GLP1-RAs are not well understood.
Purpose of the Study:
- To systematically review existing research on patient experiences with GLP1-RAs.
- To synthesize qualitative and quantitative data on patient perspectives regarding GLP1-RAs for obesity management.
Main Methods:
- Comprehensive literature search across major databases (PubMed, PsycINFO, Embase, Sociological Abstracts).
- Inclusion of studies on adult GLP1-RA users, excluding specific conditions like mental illness or PCOS.
- Thematic analysis of nine selected studies (qualitative, RCTs, reviews, survey) to synthesize findings.
Main Results:
- Patients tolerate adverse events, such as gastrointestinal issues, for successful weight loss.
- Weight loss achieved with GLP1-RAs leads to improved physical functioning and daily living.
- Patient experiences vary regarding medication usability, craving management, and gender-specific benefits.
Conclusions:
- Qualitative research on GLP1-RA patient experiences is limited despite high demand.
- Further research is essential to fully comprehend short- and long-term patient journeys with GLP1-RAs.
- Understanding patient perspectives can optimize obesity treatment strategies.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
01:17Assessment of the Gastrointestinal System I: Subjective Data
160
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
160
01:06Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
167
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
167
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178